Acadia Pharmaceuticals Reports Third Quarter 2022 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- SpaceX shares fall as second lockup period ends
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Acadia Pharmaceuticals (ACAD) PT Lowered to $16 at Stifel
November 3, 2022 11:19 AM EDTStifel analyst Paul Matteis lowered the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $16.00 (from $17.00) while maintaining a Hold rating.
The analyst commented, "We are reiterating our Hold rating on ACAD following yesterday's 3Q22 update. Nuplazid missed for the quarter ($130.7MM vs. $139.9MM), as... More
